Please find attached outcome of Board Meeting held on October 15, 2026.

October 15, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Sub.: Outcome of Board Meeting Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) The Board of Directors of Mankind Pharma Limited (“Company”), at its meeting held today, i.e., October 15, 2026, has, inter alia, considered and approved: i. an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. (“Mankind Netherlands”), a wholly owned subsidiary of the Company in Netherlands, in one or more tranches, thereby increasing the aggregate investment limit to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn; ii. the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. (“ACTx”) through Mankind Netherlands. ACTx is a Belgium-incorporated biotechnology company engaged in the development of next-generation chimeric antigen receptor T-cell (“CAR-T”) therapies for cancer. ACTx has a pipeline of next-generation CAR-T assets, with its lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Master Circular”) for above items is enclosed herewith as Annexure-I; The Press Release titled “Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies”, being released by the Company, is also enclosed herewith as Annexure-II, which is self-explanatory. The meeting of Board of Directors of the Company commenced at 06:00 p.m. (IST) and concluded at 07:00 p.m. (IST). You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Annexure-I Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular: S. Details of event that needs to be Details No. provided 1. Name of the target entity, details in Name: Mankind Pharma (Netherlands) B.V. to acquire 70% stake in brief such as size, turnover etc.; Armed Cell Therapeutics B.V. (“ACTx”) Authorized share capital: EUR 50Mn Paid-up share capital: EUR 0.02Mn Turnover: Nil 2. Whether the acquisition would fall Investment by Company into Mankind Netherlands, will be a related within related party transaction(s) party transaction, being a wholly-owned subsidiary. and whether the promoter/ promoter group/ group companies have any Since, Mankind Netherlands is a wholly owned subsidiary of the interest in the entity being acquired? Company, the aforesaid transaction between the Company and If yes, nature of interest and details Mankind Netherlands is exempt under Regulation 23(5) of SEBI thereof and whether the same is done (Listing Obligations and Disclosure Requirements) Regulations, 2015. at “arm’s length”; Except to the extent of stake held by the Company in Mankind Netherlands, the promoter/promoter group/group companies of the Company have no interest in Mankind Netherlands. The investment in ACTx by the Mankind Netherlands is not a related party transaction. 3. Industry to which the entity being Pharmaceutical Industry acquired belongs; 4. Objects and impact of acquisition The funds will be utilized by Mankind Netherlands to acquire a (including but not limited to, majority stake (i.e., 70%) in ACTx through an investment of EUR disclosure of reasons for acquisition 48Mn, to be made in instalments. of target entity, if its business is outside the main line of business of Said investment is part of the Company’s long term strategy to build a the listed entity); global innovation-led pharmaceutical business. 5. Brief details of any governmental or As may be required in compliance with laws of the host country regulatory approvals required for the acquisition; 6. Indicative time period for As per definitive agreement completion of the acquisition; 7. Consideration - whether cash Cash Consideration consideration or share swap or any other form and details of the same; 8. Cost of acquisition and/or the price The Company will make an additional investment of up to EUR 45Mn, at which the shares are acquired; in one or more tranches in Mankind Netherlands, aggregating to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn, which will be utilized to invest EUR 48Mn in installments in ACTx for acquiring 70% stake. 9. Percentage of shareholding / control The investment in Mankind Netherlands will not cause any change in acquired and / or number of shares the percentage of the Shareholding of the Company. It will continue to acquired; remain a wholly-owned subsidiary of the Company. 10. Brief background about the entity The Mankind Netherlands is an existing wholly owned subsidiary of acquired in terms of products/line of the Company, incorporated in Netherlands on August 13, 2026, with business acquired, date of the business objective of holding investments in R&D assets and incorporation, history of last 3 years undertaking business development activities focused on the treatment turnover, country in which the of niche therapies, either through joint ventures or by acquiring acquired entity has presence and any strategic interests as opportunities arise. The Mankind Netherlands was other significant information (in incorporated recently, hence turnover is Nil. brief); ACTx, a Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T cell) therapies for cancer and has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. ACTx R&D activities are led by highly experienced teams located in US and EU. Annexure-II Press Release Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies Armed Cell Therapeutics is a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer. New Delhi, India, 15th October, 2026: As a part of its long term strategy to build a global innovation- led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer. Transaction Summary:  Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics  Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer  ACTx will pursue innovative means of CAR- T cell therapy including in vivo CAR-T cell generation  ACTx’s R&D activities are led by highly experienced teams located in US and EU Armed Cell Therapeutics was founded by a team with experience in drug development, cell therapy and building companies. Its founders, include Paul Stoffels, MD, Chair of the Board, former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson; John Mellors, MD, Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former SVP Discovery and Early Development at Galapagos; and Peter Verhaeghe, former Chair of argenx. CAR-T therapies have transformed the treatment of some blood cancers. Yet many patients relapse from lack of CAR-T cell persistence, CAR-T exhaustion or emergence of resistant cancer [Showing first 8,000 characters — download PDF for full document]